According to filings with the U.S. Securities and Exchange Commission, 858 Therapeutics is raising up to $50,350,497.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Jeffrey Stafford played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About 858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology. 858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell genomics, and innate immunity, 858 scientists are dedicated to the companys mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies. 858 is headquartered in the biotech hub of San Diego, CA, and maintains lab operations in both San Diego and New York City, providing proximity to leading investigators and scientific talent on both coasts of the US.

To learn more about 858 Therapeutics, visit http://www.8five8tx.com/
858 Therapeutics Linkedin Page: https://www.linkedin.com/company/858-therapeutics/

Contact:
Jeffrey Stafford, President and Chief Executive Officer
858-987-8380
https://www.linkedin.com/in/jeffrey-stafford-7b878010/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.